necessary items, decrease in spending frequency and low-price favorable from consumer and retailer must also rely on promotion and marketing campaign. (Source : 3Q18 BOT Economic Report/EIC Outlook quarter 4

year, mostly from revenue from UAC which increased Baht 977.69 million, which resulted in the increase in gross profit of Baht 20.62 million and the decrease in gross profit margin for 9-month period of

17.74% 20.03 9.21% 49.42 246.73% Jul – Sep 63 Jul – Sep 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขที่ 111 หมู่ที่ 2 ตาํบลท่าจนี อาํเภอเมืองสมุทรสาคร จงัหวดัสมุทรสาคร 74000 111 Moo 2

and its subsidiary for the third quarter ended September 30, 2019 which the details are as follows: Unit: million Baht For 3-month period (July-Sep) 2019 2018 Change % Increase (Decrease) Revenue from

in Q1-2023. Total operating expenses in Q2-2023 have changed in the same direction and at a similar rate with the increase and decrease in revenue when compared to Q1- 2023 and Q2- 2022. However, the

million, an decrease of Bt6.3 million or 2.7% (y-o-y) from Bt237.5 million, representing a net profit margin of 26.3% which has an earnings per share of Bt0.36. Excluding these special item, the net profit

service of Baht 793.67 million compared with Baht 839.34 million in the same period of the previous year, which decreased by 5.4 percent. The decrease in sales was due to the decrease in overall sales

, 2016, and 2015 Unit: Baht million 2017 % 2016 % Increased (Decrease) % 2015 % Increased (Decrease) % Revenue from sales and services 49,269.3 100.00 46,887.3 100.00 2,382.0 5.1% 46,938.2 100.00 2,331.1

services amounted to Baht 274 million, decreased by Baht 1,021 million or 79% YoY. Net loss resulted from total revenue from sales and services of the Company and subsidiary decrease together with high level

of income generating assets from the EBT of UE since 16 March 2018, whose revenue contribution this quarter amounted to THB 119mn, being partially offset by (iii) a decrease of 25.8% YoY or THB 29mn of